---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-094869"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2026-08-12T20:07:37+00:00"
generated_at: "2026-08-12T20:09:41.406045+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ArriVent reports H1 results and licenses ARR-002 to Allist for up to $80.6M

## Summary
- Entered exclusive license with Allist for ARR-002 in Greater China; potential $80.6M in upfront, milestones, plus tiered royalties (mid-single to low-double digit).
- Cash and investments $373.1M at June 30, 2026; expected to fund operations into 2028.
- Net loss $93.2M for H1 2026 vs $95.8M in H1 2025; R&D $80.0M, G&A $18.8M.
- Firmonertinib Phase 3 FURVENT topline data for EGFR exon20 NSCLC expected 2H 2026.
- ARR-002 first patient dosing expected Q3 2026; ARR-217 advanced to Phase 1b dose optimization.

## SEC filing metadata
- accession: 0001104659-26-094869
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2026-08-12T20:07:37+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/0001104659-26-094869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/tm2622880d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-094869
- JSON: https://secwatch.observer/filing/0001104659-26-094869.json
- Plain text: https://secwatch.observer/filing/0001104659-26-094869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.